Comparative Pharmacology
Head-to-head clinical analysis: ADLARITY versus ARICEPT ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADLARITY versus ARICEPT ODT.
ADLARITY vs ARICEPT ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADLARITY is a transdermal formulation of donepezil, a reversible acetylcholinesterase inhibitor that increases acetylcholine levels in the central nervous system, improving cholinergic neurotransmission in the cerebral cortex.
Reversible acetylcholinesterase inhibitor, increasing acetylcholine concentration in the synaptic cleft of central cholinergic neurons.
10 mg transdermal patch applied once daily to clean, dry, hairless skin on the back, chest, or upper arm.
5 mg orally once daily; may increase to 10 mg once daily after 4-6 weeks.
None Documented
None Documented
Terminal half-life approximately 70 hours (range 50-100 hours); steady-state achieved within 14-21 days; once-daily dosing due to long half-life.
Terminal elimination half-life: 70 hours (range 50-80 hours). Clinical context: Steady-state achieved in 15-21 days; once-daily dosing maintains therapeutic concentrations.
Renal: ~60% as unchanged donepezil and metabolites (primarily donepezil, 6-O-desmethyl donepezil, and donepezil-N-oxide); fecal: ~15-20% (biliary excretion of metabolites); minor via urine as conjugates.
Renal: 57% (as unchanged drug and metabolites); Fecal: 15%; Biliary: minor
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor